|
US6046166A
(en)
*
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6037323A
(en)
*
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6004925A
(en)
*
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6287590B1
(en)
|
1997-10-02 |
2001-09-11 |
Esperion Therapeutics, Inc. |
Peptide/lipid complex formation by co-lyophilization
|
|
WO2000059855A1
(en)
|
1999-04-01 |
2000-10-12 |
Esperion Therapeutics, Inc. |
Ether compounds, compositions, and uses thereof
|
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
US20090017069A1
(en)
|
2000-06-29 |
2009-01-15 |
Lipid Sciences, Inc. |
SARS Vaccine Compositions and Methods of Making and Using Them
|
|
US7407662B2
(en)
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified viral particles with immunogenic properties and reduced lipid content
|
|
US7148197B2
(en)
*
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
|
US6664230B1
(en)
*
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US7199102B2
(en)
*
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7723303B2
(en)
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
|
US7166578B2
(en)
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
CN1268641C
(zh)
|
2000-11-10 |
2006-08-09 |
普罗蒂奥制药公司 |
载脂蛋白类似物
|
|
SI1335938T1
(sl)
*
|
2000-11-10 |
2011-01-31 |
Hoffmann La Roche |
Apolipoproteinski konstrukt
|
|
WO2003000381A1
(en)
*
|
2001-06-25 |
2003-01-03 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
US6991727B2
(en)
*
|
2001-06-25 |
2006-01-31 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
US20050260256A1
(en)
*
|
2001-09-28 |
2005-11-24 |
Hill Knut R |
Methods and apparatus for extrusion of vesicles at high pressure
|
|
PL372925A1
(en)
*
|
2001-09-28 |
2005-08-08 |
Esperion Therapeutics Inc. |
Prevention and treatment of restenosis by local administration of drug
|
|
US7470659B2
(en)
*
|
2001-12-07 |
2008-12-30 |
The Regents Of The University Of California |
Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
|
|
AU2002360489A1
(en)
*
|
2001-12-07 |
2003-06-23 |
The Regents Of The University Of California |
Treatment for age-related macular degeneration
|
|
US20030229062A1
(en)
*
|
2001-12-07 |
2003-12-11 |
The Regents Of The University Of California |
Treatments for age-related macular degeneration (AMD)
|
|
US6930085B2
(en)
|
2002-04-05 |
2005-08-16 |
The Regents Of The University Of California |
G-type peptides to ameliorate atherosclerosis
|
|
US20040009216A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Rodrigueza Wendi V. |
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
|
|
US20100204103A1
(en)
*
|
2002-05-08 |
2010-08-12 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
NZ537006A
(en)
*
|
2002-05-17 |
2008-01-31 |
Esperion Therapeutics Inc |
The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
|
|
CA2486127C
(en)
*
|
2002-05-17 |
2014-03-11 |
Esperion Therapeutics, Inc. |
Method of treating dyslipidemic disorders
|
|
NL1020962C2
(nl)
*
|
2002-06-28 |
2003-12-30 |
Tno |
Therapie en prognose/monitoring bij sepsis en septische shock.
|
|
US20050101565A1
(en)
*
|
2002-07-03 |
2005-05-12 |
Esperion Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating, preventing, and managing cholesterol, dyslipidemia, and related disorders
|
|
US9655865B2
(en)
|
2002-07-29 |
2017-05-23 |
Veroscience, Llc |
Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
|
|
US20040220190A1
(en)
*
|
2002-07-29 |
2004-11-04 |
Cincotta Anthony H. |
Methods of treating metabolic syndrome using dopamine receptor agonists
|
|
US20080200453A1
(en)
|
2002-07-29 |
2008-08-21 |
Cincotta Anthony H |
Methods of treating metabolic syndrome using dopamine receptor agonists
|
|
US8821915B2
(en)
|
2002-08-09 |
2014-09-02 |
Veroscience, Llc |
Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
|
|
US20040081678A1
(en)
*
|
2002-08-09 |
2004-04-29 |
Anthony Cincotta |
Therapeutic process for the treatment of obesity and associated metabolic disorders
|
|
CA2503284A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Enos Pharmaceuticals, Inc. |
Sustained release l-arginine formulations and methods of manufacture and use
|
|
PT2404890T
(pt)
|
2003-01-23 |
2017-10-23 |
Esperion Therapeutics Inc |
Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas
|
|
US7393826B2
(en)
|
2003-07-03 |
2008-07-01 |
Lipid Sciences, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
|
DK2368565T3
(en)
|
2003-07-03 |
2015-09-28 |
Hdl Therapeutics Inc |
Enrichment of pre-beta lipoproteins, high density
|
|
EP1706131A4
(de)
*
|
2003-12-15 |
2009-08-12 |
Univ California |
Den zellulären cholesterin-efflux stimulierende helikale synthetische peptide
|
|
EP1699527A1
(de)
|
2004-01-02 |
2006-09-13 |
Advanced Cardiovascular Systems, Inc. |
Mit lipoprotein hoher dichte beschichtete medizinprodukte
|
|
US8137994B2
(en)
*
|
2004-03-25 |
2012-03-20 |
Veroscience Llc |
Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
|
|
US8137993B2
(en)
*
|
2004-03-25 |
2012-03-20 |
Veroscience Llc |
Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
|
|
US20050215558A1
(en)
*
|
2004-03-25 |
2005-09-29 |
Cincotta Anthony H |
Methods of identifying responders to dopamine agonist therapy
|
|
WO2005097206A2
(en)
*
|
2004-04-06 |
2005-10-20 |
Cedars-Sinai Medical Center |
Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
|
|
EP1602931A1
(de)
*
|
2004-06-03 |
2005-12-07 |
Universiteit Leiden |
SR-A Antagonisten
|
|
UY28953A1
(es)
*
|
2004-06-09 |
2006-01-31 |
Avanir Pharmaceuticals |
Derivados heterocíclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas
|
|
WO2005123770A1
(en)
*
|
2004-06-09 |
2005-12-29 |
Avanir Pharmaceuticals |
Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
|
|
US20050277690A1
(en)
*
|
2004-06-09 |
2005-12-15 |
Sircar Jagadish C |
Small molecules for treatment of hypercholesterolemia and related diseases
|
|
WO2007018550A2
(en)
*
|
2004-09-08 |
2007-02-15 |
The United States Of America As Represented By The Secretary Of Health And Human Services, Nih |
Compositions and methods for the detection of hiv-1/hiv-2 infection
|
|
WO2006034056A2
(en)
*
|
2004-09-16 |
2006-03-30 |
The Regents Of The University Of California |
G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
|
|
DE602005021534D1
(de)
|
2004-10-15 |
2010-07-08 |
Us Gov Health & Human Serv |
Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
|
|
KR20070089996A
(ko)
|
2004-12-06 |
2007-09-04 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
세동맥의 구조 및 기능의 개선 방법
|
|
US7759315B2
(en)
|
2005-03-09 |
2010-07-20 |
Csl Behring Ag |
Treatment of inflammatory conditions of the intestine
|
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
|
WO2006118805A2
(en)
*
|
2005-04-29 |
2006-11-09 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
WO2006125304A1
(en)
*
|
2005-05-25 |
2006-11-30 |
Liponex, Inc. |
Pharmaceutical compositions for treating or preventing coronary artery disease
|
|
GR1005428B
(el)
*
|
2005-05-27 |
2007-02-01 |
Χαραλαμπος Αλεξοπουλος |
Συνθετικα λιποπεπτιδια με αντιαθηρογονο δραση, που εμποδιζουν την οξειδωση της λιποπρωτεϊνης χαμηλης πυκνοτητας (ldl) και αναστελλουν την απενεργοποιηση του ενζυμου της paf ακετυλοϋδρολασης (paf-ah)
|
|
WO2007024863A2
(en)
|
2005-08-22 |
2007-03-01 |
Melior Discovery, Inc. |
Methods and formulations for modulating lyn kinase activity and treating related disorders
|
|
GB0602598D0
(en)
*
|
2006-02-09 |
2006-03-22 |
Cheesmond David |
Quick change front F2 sidecar
|
|
US20070254832A1
(en)
*
|
2006-02-17 |
2007-11-01 |
Pressler Milton L |
Methods for the treatment of macular degeneration and related eye conditions
|
|
TW200744627A
(en)
*
|
2006-02-21 |
2007-12-16 |
Pfizer Prod Inc |
Methods for the treatment of macular degeneration and related eye conditions
|
|
US8163699B2
(en)
*
|
2006-06-01 |
2012-04-24 |
Montreal Heart Institute |
Method for the treatment of valvular disease
|
|
US20080227686A1
(en)
*
|
2006-06-16 |
2008-09-18 |
Lipid Sciences, Inc. |
Novel Peptides that Promote Lipid Efflux
|
|
EP2041174A2
(de)
*
|
2006-06-16 |
2009-04-01 |
Lipid Sciences, Inc. |
Neue, den lipidausstrom fördernde peptide
|
|
US20080206142A1
(en)
*
|
2006-06-16 |
2008-08-28 |
Lipid Sciences, Inc. |
Novel Peptides That Promote Lipid Efflux
|
|
WO2008021088A2
(en)
|
2006-08-08 |
2008-02-21 |
The Regents Of The University Of Californina |
Salicylanilides enhance oral delivery of therapeutic peptides
|
|
US20080138284A1
(en)
*
|
2006-09-26 |
2008-06-12 |
Lipid Sciences, Inc. |
Novel Peptides That Promote Lipid Efflux
|
|
WO2008094939A1
(en)
*
|
2007-01-31 |
2008-08-07 |
Nutrition 21, Inc. |
Use of chromium histidinate for treatment of cardiometabolic disorders
|
|
US20100152215A1
(en)
*
|
2007-02-20 |
2010-06-17 |
Melior Pharmaceuticals I, Inc. |
Methods of identifying activators of lyn kinase
|
|
DK1964571T3
(da)
|
2007-03-01 |
2012-08-13 |
Csl Ltd |
Behandling af endothelial dysfunktion hos diabetespatienter
|
|
ES2579229T3
(es)
|
2007-03-13 |
2016-08-08 |
Jds Therapeutics, Llc |
Procedimientos y composiciones para la liberación sostenida de cromo
|
|
WO2009002867A2
(en)
|
2007-06-26 |
2008-12-31 |
Nutrition 21, Inc. |
Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
|
|
AU2008279242A1
(en)
*
|
2007-07-23 |
2009-01-29 |
Melior Discovery, Inc. |
Methods of activating IRS-1 and AKT
|
|
US8431529B2
(en)
*
|
2007-07-31 |
2013-04-30 |
Sanford-Burnham Medical Research Institute |
Bi-dentate compounds as kinase inhibitors
|
|
CA2695384A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Burnham Institute For Medical Research |
Bi-dentate compounds as kinase inhibitors
|
|
EP2195340A4
(de)
|
2007-08-28 |
2011-05-11 |
Uab Research Foundation |
Synthetische apolipoprotein e-imitierende polypeptide und verwendungsverfahren
|
|
EP2682400B1
(de)
|
2007-08-28 |
2017-09-20 |
Uab Research Foundation |
Synthetische Apolipoprotein E nachahmende Polypeptide und Anwendungsverfahren
|
|
EP2182956A2
(de)
*
|
2007-08-29 |
2010-05-12 |
The Regents of the University of California |
Salicylanilidmodifizierte peptide zur verwendung als orale therapeutika
|
|
US7985727B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Apo A-I mimetic peptides and methods of treatment
|
|
US8044021B2
(en)
*
|
2007-09-20 |
2011-10-25 |
Abbott Cardiovascular Systems Inc. |
Sustained release of apo A-I mimetic peptides and methods of treatment
|
|
US7985728B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US9173890B2
(en)
*
|
2007-09-20 |
2015-11-03 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US8101565B2
(en)
*
|
2007-09-20 |
2012-01-24 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
WO2009129263A1
(en)
*
|
2008-04-15 |
2009-10-22 |
The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. |
Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
|
|
US8552184B2
(en)
*
|
2008-07-03 |
2013-10-08 |
Melior Pharmaceuticals I, Inc. |
Compounds and methods for treating disorders related to glucose metabolism
|
|
EP3284482B1
(de)
|
2008-11-10 |
2020-06-03 |
Arbutus Biopharma Corporation |
Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
|
|
WO2010083611A1
(en)
|
2009-01-23 |
2010-07-29 |
Institut De Cardiologie De Montreal |
Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex
|
|
CA2751342C
(en)
|
2009-01-29 |
2019-05-07 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
|
|
EP2939683B1
(de)
|
2009-02-16 |
2017-01-04 |
Cerenis Therapeutics Holding SA |
Apolipoprotein A-I-Mimetika
|
|
CN104922699B
(zh)
|
2009-03-12 |
2020-07-24 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
|
|
NZ621981A
(en)
|
2009-05-05 |
2015-09-25 |
Tekmira Pharmaceuticals Corp |
Lipid compositions
|
|
WO2010135663A2
(en)
|
2009-05-21 |
2010-11-25 |
The United States Of America , As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for the detection of hiv-1/hiv-2 infection
|
|
US9352025B2
(en)
|
2009-06-05 |
2016-05-31 |
Veroscience Llc |
Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
|
|
CA3014827A1
(en)
|
2009-06-10 |
2010-12-16 |
Jianxin Chen |
Improved cationic lipid of formula i
|
|
AP2015008874A0
(en)
|
2009-08-14 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
CN102753576A
(zh)
*
|
2009-09-30 |
2012-10-24 |
首尔大学教产学协力团 |
载脂蛋白a-1模拟肽以及包含其的用于治疗高血脂及高血脂相关疾病的治疗剂
|
|
US10894098B2
(en)
|
2012-04-09 |
2021-01-19 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
|
WO2011044545A2
(en)
|
2009-10-09 |
2011-04-14 |
Sigalov Alexander B |
Methods and compositions for targeted imaging
|
|
EP2509636B1
(de)
|
2009-12-07 |
2017-07-19 |
Arbutus Biopharma Corporation |
Zusammensetzungen für nukleinsäurefreisetzung
|
|
EP2512449B1
(de)
|
2009-12-18 |
2019-08-07 |
The University of British Columbia |
Verfahren und zusammensetzungen zur abgabe von nukleinsäuren
|
|
US20110152112A1
(en)
*
|
2009-12-23 |
2011-06-23 |
Artery Therapeutics, Inc. |
Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
|
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
US20130137628A1
(en)
|
2010-05-11 |
2013-05-30 |
Esperion Therapeutics, Inc. |
Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
|
|
US20130158055A1
(en)
|
2010-05-28 |
2013-06-20 |
Andrew G. Reaume |
Prevention Of Pancreatic Beta Cell Degeneration
|
|
EP2575764B1
(de)
|
2010-06-03 |
2017-04-19 |
Alnylam Pharmaceuticals, Inc. |
Biologisch abbaubare lipide zur freisetzung von aktiven verbindungen
|
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
|
WO2012064824A1
(en)
|
2010-11-09 |
2012-05-18 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
|
US8728749B2
(en)
|
2010-12-31 |
2014-05-20 |
Bruce J. Auerbach |
Detection of LCAT activity
|
|
WO2012099755A1
(en)
|
2011-01-11 |
2012-07-26 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
|
KR20140053848A
(ko)
|
2011-02-07 |
2014-05-08 |
세레니스 쎄라퓨틱스 홀딩 에스에이 |
지단백질 복합체 및 그의 제조 및 용도
|
|
EP2680861B1
(de)
|
2011-03-01 |
2022-05-04 |
Nutrition 21, LLC |
Zusammensetzungen enthaltend insulin und chrom zur behandlung und vorbeugung von diabetes und hypoglykämie und verwandten krankheiten
|
|
CA2849476A1
(en)
|
2011-09-27 |
2013-04-04 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
|
MX353660B
(es)
*
|
2011-11-30 |
2018-01-23 |
Dae Woong Pharma |
Composicion farmaceutica para evitar o tratar hiperlipidemia.
|
|
SG11201403207WA
(en)
|
2011-12-12 |
2014-09-26 |
Melior Pharmaceuticals I Inc |
Treatment of type i and type ii diabetes
|
|
SG11201507287SA
(en)
|
2013-03-15 |
2015-10-29 |
Univ California |
Peptides having reduced toxicity that stimulate cholesterol efflux
|
|
EP2853259A1
(de)
|
2013-09-30 |
2015-04-01 |
Université Pierre et Marie Curie (Paris 6) |
Rekonstituierte hochdichte Lipoproteinzusammensetzung und Verwendungen davon
|
|
AU2015260929A1
(en)
|
2014-05-02 |
2016-12-15 |
Cerenis Therapeutics Holding Sa |
HDL therapy markers
|
|
WO2016011049A2
(en)
|
2014-07-14 |
2016-01-21 |
Schwendeman Anna |
Compositions and methods for disease treatment using nanoparticle delivered compounds
|
|
EP3189069B1
(de)
|
2014-07-31 |
2024-10-23 |
UAB Research Foundation |
Apoe-mimetische peptide und erhöhte wirksamkeit für klares plasmacholesterol
|
|
NZ736344A
(en)
|
2015-03-13 |
2024-08-30 |
Esperion Therapeutics Inc |
Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
|
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
|
BR112017020491A2
(pt)
*
|
2015-03-25 |
2018-07-17 |
The Regents Of The University Of Michigan |
composições e métodos para distribuição de agentes de biomacromolécula.
|
|
WO2016154542A2
(en)
*
|
2015-03-25 |
2016-09-29 |
The Regents Of The University Of Michigan |
Compositions and methods for treating cardiovascular related disorders
|
|
US10532105B2
(en)
|
2015-07-10 |
2020-01-14 |
Peptinovo Biopharma, LLC. |
Formulations for improving the efficacy of hydrophobic drugs
|
|
WO2017139337A1
(en)
|
2016-02-11 |
2017-08-17 |
Nutrition 21, Llc |
Chromium containing compositions for improving health and fitness
|
|
US20190167767A1
(en)
|
2016-07-27 |
2019-06-06 |
Hartis-Pharma Sa |
Therapeutic combinations to treat red blood cell disorders
|
|
FR3061715B1
(fr)
*
|
2017-01-12 |
2021-07-30 |
Institut National Univ Jean Francois Champollion |
Peptide immunomodulateur
|
|
SG11201909406VA
(en)
|
2017-04-10 |
2019-11-28 |
Melior Pharmaceuticals I Inc |
Treatment of adipocytes
|
|
EP3668600B1
(de)
|
2017-08-10 |
2024-05-15 |
Abionyx Pharma SA |
Cargomere
|
|
EP3687538B1
(de)
|
2017-10-30 |
2024-04-17 |
Montreal Heart Institute |
Verfahren zur behandlung von erhöhtem plasmacholesterin
|
|
WO2019104237A1
(en)
|
2017-11-22 |
2019-05-31 |
Hdl Therapeutics, Inc. |
Systems and methods for priming fluid circuits of a plasma processing system
|
|
CA3087207A1
(en)
|
2017-12-28 |
2019-07-04 |
Hdl Therapeutics, Inc. |
Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
|
|
CN110294791B
(zh)
*
|
2019-06-13 |
2023-02-21 |
倪京满 |
具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
|
|
WO2020257573A1
(en)
|
2019-06-21 |
2020-12-24 |
Esperion Therapeutics, Inc. |
Salt forms of bempedoic acid and methods for using the same
|
|
MX2022012969A
(es)
|
2020-04-16 |
2022-11-09 |
Abionyx Pharma Sa |
Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.
|
|
JP2023543498A
(ja)
|
2020-10-01 |
2023-10-16 |
アビオニクス ファーマ エスエー |
脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
|
|
IL307670A
(en)
|
2021-04-15 |
2023-12-01 |
Abionyx Pharma Sa |
Use of lipid-binding protein-based complexes in organ preservation solutions
|
|
WO2023194797A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
|
WO2023194798A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
|
|
WO2023237927A2
(en)
|
2022-06-10 |
2023-12-14 |
Abionyx Pharma Sa |
Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
|
|
WO2023237935A2
(en)
|
2022-06-10 |
2023-12-14 |
Abionyx Pharma Sa |
Methods for treating acute conditions using lipid binding protein-based complexes
|
|
WO2024150064A1
(en)
|
2023-01-13 |
2024-07-18 |
Abionyx Pharma Sa |
Lipid binding protein molecule therapy
|